All issues
Volume 118, Issue 1
Displaying 1-8 of 8 articles from this issue
- |<
- <
- 1
- >
- >|
Reviews: Frontiers in Histamine Research in the Peripheral Tissue
-
Yasuo ENDOSubject area: Others
2001 Volume 118 Issue 1 Pages 5-14
Published: 2001
Released on J-STAGE: September 27, 2002
JOURNAL FREE ACCESSHistamine is a classical, but still interesting inflammatory mediator. Many people have long believed that histamine is derived from mast cells or basophils alone. However, the histamine-forming enzyme, histidine decarboxylase (HDC), is induced in a variety of tissues in response (i) to gram-positive and gram-negative bacterial components (lipopolysaccharides, peptidoglycan, and enterotoxin A) and (ii) to various cytokines (IL-1, IL-3, IL-12, IL-18, TNF, G-CSF, and GM-CSF). HDC is induced even in mast-cell-deficient mice. The histamine newly formed via the induction of HDC is released immediately and may be involved in a variety of immune responses. Reviewing our work and that of Schayer and Kahlson, the pioneers in this field, lead us to the conclusion that nowadays we need to understand that histamine can be produced via the induction of HDC by a mechanism coupled with the cytokine network. We call this histamine “neohistamine”, to distinguish it from the classical histamine derived from mast cells or basophils. Neohistamine is involved in physiological reactions, inflammation, immune responses and a variety of diseases such as periodontitis, muscle fatigue (or temporomandibular disorders), stress- or drug-induced gastric ulcers, rheumatoid arthritis, complications in diabetes, hepatitis, allograft rejection, allergic reactions, tumor growth, and inflammatory side effects of aminobisphosphonates.View full abstractDownload PDF (1062K) -
Kiwao NAKANO, Shinji TAKAMATSUSubject area: Others
2001 Volume 118 Issue 1 Pages 15-22
Published: 2001
Released on J-STAGE: September 27, 2002
JOURNAL FREE ACCESSMacrophages (Mφ) produce histamine (Hm) when activated by bacterial endotoxin (LPS) through induced histidine decarboxylase (HDC). Among the cytokines tested, GM-CSF or IL-3 specifically augmented the LPS-depndent HDC induction by Mφ. Hm formed by Mφ regulates synthesis of cytokines such as IL-1, IL-6, G-CSF and M-CSF by the cells per se and may modulate immune reactions and division and differentiation of various hematopoietic cells. Kupffer cells, Mφ-like cells in the liver, also synthesize Hm in mice injected with hepatotoxins such as tetradecanoylphorbol acetate or LPS. Hm thus produced by Kupffer cells may participate in the regeneration of the injured liver through induction of hepatocyte growth factor. Concanavalin A (Con A) enhanced Hm formation by T lymphocytes. GM-CSF or IL-3 also enhanced the Hm synthesis by CD4+ and CD8+ T cells. Hm formed by T cells regulates immune reactions such as lymphocyte blastogenesis. In animals infected with gram (−) bacteria Hm is produced by the Mφ-T cell system and may regulate immune competence to the bacteria. In addition, Hm may act as a signal transducer between the peripheral immune system and hypothalamus-pituitary-adrenal system, leading to GC secretion, in order to prevent occurrence of tissue injury caused by excess immune reactions.View full abstractDownload PDF (1810K) -
Noriyasu HIRASAWA, Kazuo OHUCHISubject area: Others
2001 Volume 118 Issue 1 Pages 23-28
Published: 2001
Released on J-STAGE: September 27, 2002
JOURNAL FREE ACCESSStimulating cells of the mouse macrophage-like cell line RAW 264.7 with the Ca2+-ATPase inhibitor thapsigargin increased histamine production. Thapsigargin increased the levels of histidine decarbxylase (HDC) mRNA at 4 h and the expression of 74-kDa HDC protein at 8 h. PD98059, a specific inhibitor of MEK-1 which phosphorylates p44/p42 MAP kinase, strongly suppressed the thapsigargin-induced histamine production, the increase in HDC mRNA level and 74-kDa HDC protein expression. In contrast, SB203580, an inhibitor of p38 MAP kinase, showed only a partial inhibition of histamine production. TPA and LPS also induced histamine production in RAW 264.7 cells, and the histamine production induced by TPA or LPS was also inhibited by PD98059, but the effect of SB203580 was partial. The synthetic glucocorticoid dexamethasone inhibited thapsigargin-induced histamine production, 74-kDa HDC protein expression and the activation of p44/p42 MAP kinases. In conclusion, the increase in histamine production in macrophages stimulated with inflammatory stimulants is due to the increased expression of 74-kDa HDC, which is positively regulated by activated p44/p42 MAP kinases. Dexamethasone inhibits thapsigargin-induced HDC protein expression and histamine production by inhibiting the MAP kinase activation.View full abstractDownload PDF (986K) -
Masahiro NISHIBORI, Hideo KOHKA-TAKAHASHI, Shuji MORISubject area: Others
2001 Volume 118 Issue 1 Pages 29-35
Published: 2001
Released on J-STAGE: September 27, 2002
JOURNAL FREE ACCESSHistamine is a well known mediator of inflammation including the allergic reaction. Histamine has been suggested to be a immunomodulator. Recent studies revealed that induction of histidine decarboxylase occurs by the stimulation of several cytokines and LPS, suggesting an immunomodulatory role of the inducible histamine. Using human PBMC culture, it was demonstrated that histamine was a potent inducer of IL-18, IFN-γ in human PBMC. Histamine did not induce the production of IL-12. The effects of histamine on cytokine production were mimicked by H2-selective agonists and inhibited by H2- but not by H1- and H3- antagonists, indicating the involvement of H2- receptors in histamine action. All effects of histamine were abolished by the presence of anti-IL-18 antibody or IL-1b-converting enzyme/caspase-1 inhibitor, indicating that histamine action is dependent on mature IL-18 secretion and that IL-18 production was present most upstream of the cytokine cascade triggered by histamine. Histamine is a very important modulator of Th1 cytokine production in PBMC and is quite unique in triggering the cytokine cascade without inducing IL-12 production.View full abstractDownload PDF (878K) -
Tamaki ODA, Shun-ichiro MATSUMOTOSubject area: Others
2001 Volume 118 Issue 1 Pages 36-42
Published: 2001
Released on J-STAGE: September 27, 2002
JOURNAL FREE ACCESSRecently, we and other groups have identified cDNA encoding the novel histamine H4 receptor. All of the groups have initially found a clue for the H4 receptor-nucleotides sequence in the human draft genomic DNA database. The primary structure of H4 receptor reveals the highest homology with H3 receptor among known G-protein coupled receptors (37.4%). H4 receptor binds to histamine with high affinity, which results in the down-regulation of intracellular cAMP level. H4 receptor is activated not only by histamine, but also R-(α)-methylhistamine (H3 receptor agonist), clobenpropit (H3 receptor antagonist), clozapine (neuroleptic) and other histaminergic compounds, while it is antagonized by thioperamide (H3 receptor antagonist). The H4 receptor is localized in the peripheral blood leukocytes, spleen, thymus, small intestine, colon, bone marrow and so on. The tissue distribution of the H4 receptor and known physiological function of histamine tempts us to speculate about its function as an immune modulator. Although there needs much additional work on characterization of the H4 receptor, the discovery of this receptor subtype will unveil a new phase for determining the physiological role of histamine.View full abstractDownload PDF (794K) -
Hitoshi KASHIBA, Emiko SENBASubject area: Others
2001 Volume 118 Issue 1 Pages 43-49
Published: 2001
Released on J-STAGE: September 27, 2002
JOURNAL FREE ACCESSPharmacological studies have suggested that a subgroup of primary sensory neurons is responsive to histamine via the H1 receptor. However, which type of primary sensory neurons express H1 receptor is not known. We addressed this issue using in situ hybridization histochemistry with a cRNA probe for the guinea pig H1 receptor mRNA. H1 receptor mRNA was expressed in about 15-20% of the trigeminal and lumbar dorsal root ganglion (DRG) neurons, but none of the nodose ganglion neurons. The positive neurons in DRG were exclusively small in size and were labeled by isolectin B4, suggesting that these neurons have unmyelinated fibers. However, H1-receptor mRNA-expressing DRG neurons were not immunoreactive to substance P (SP) or calcitonin gene-related peptide (CGRP), which are implicated in the nociceptive transmission of the primary sensory system. Moreover, in guinea pigs neonatally treated with capsaicin (50 mg/kg), few CGRP-immunoreactive neurons were seen in DRG, but the percentage of H1-receptor mRNA-expressing neurons (15%-20%) and the intensity of the mRNA signals in these neurons were not affected by neonatal capsaicin treatment, suggesting that H1 receptor-expressing neurons are not sensitive to capsaicin. These findings suggest that H1-receptor-expressing neurons are involved in the transmission of a unique sensory modality such as itch. A marked increase in the number of mRNA-positive DRG neurons was observed 1-5 days after a crush injury of the sciatic nerve (3-4-fold of the control value). These neurons that turned mRNA-positive after the nerve crush were also mainly small-sized. The mRNA signals were detected in many peptidergic (SP/CGRP) neurons, in contrast to the normal condition. On the other hand, mRNA signals were decreased in the neurons that showed intense labeling in the normal condition. These results suggest that the gene expression of H1 receptors up-regulated in injured afferents may be involved in neuropathic pain.View full abstractDownload PDF (1470K)
Review on New Drug
-
Kenji OHMORI, Toshihide IKEMURA, Hiroyuki KOBAYASHI, Akimichi MUKOUYAM ...Subject area: Others
2001 Volume 118 Issue 1 Pages 51-58
Published: 2001
Released on J-STAGE: September 27, 2002
JOURNAL FREE ACCESSOlopatadine is a selective histamine H1-receptor antagonist possessing inhibitory effects on the release of inflammatory lipid mediators such as leukotriene and thromboxane from human polymorphonuclear leukocytes and eosinophils. Olopatadine also inhibited the tachykininergic contraction in the guinea pig bronchi by prejunctional inhibition of peripheral sensory nerves. Oral administration of olopatadine inhibited passive cutaneous anaphylaxis in rats, experimental allergic rhinitis and bronchial asthmatic responses in actively sensitized guinea pigs. Olopatadine exerted no significant effects on action potential duration in isolated guinea pig myocardium and ventricular myocytes. Olopatadine was highly and rapidly absorbed in healthy volunteers. The urinary excretion of olopatadine accounted for not less than 58% and the contribution of metabolism was low in the elimination of olopatadine. Olopatadine was shown to be useful for the treatment of allergic rhinitis and chronic urticaria in double-blind clinical trials. Olopatadine was approved in Japan for the treatment of allergic rhinitis, chronic urticaria, eczema dermatitis, prurigo, pruritus cutaneous, psoriasis vulgaris and erythema exsudativum multiforme in December, 2000.View full abstractDownload PDF (1031K) -
Katsuhiro BANDO, Yoshikazu YAMADASubject area: Others
2001 Volume 118 Issue 1 Pages 59-67
Published: 2001
Released on J-STAGE: September 27, 2002
JOURNAL FREE ACCESSIn Type 2 diabetes, it is considered that the lowered insulin secretion and the lowered insulin sensitivity cause hyperglycemia. Sulfonylureas have strong blood-glucose lowering effect by stimulating insulin secretion and have been widely used in the treatment of Type 2 diabetes. However, the use of sulfonylurea has several problematic issues (weight gain, hypoglycemia, second failure and so on), which would due to stimulation of strong insulin secretion. Glimepiride, a new sulfonylurea, has a blood-glucose lowering effect as strong as those of existing sulfonylureas, but only induces mild insulin secretion. The sulfonylurea receptor has a weaker affinity for glimepiride than glibenclamide. The association and dissociation to the sulfonylurea receptor of glimepiride are faster than those of glibenclamide. Additionally, it is confirmed by basic studies that part of the glimepiride effect is attributable to improving insulin sensitivity. Glimepiride has already been used in more than 60 countries in the world. Outside of Japan, several clinical studies have demonstrated that glimepiride shows less hypoglycemia and no weight gain. Glimepiride is expected to be a new efficient agent for the treatment of Type 2 diabetes.View full abstractDownload PDF (663K)
- |<
- <
- 1
- >
- >|